BCAL Diagnostics (ASX:BDX) Change In Payables And Accrued Expense : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Change In Payables And Accrued Expense?

BCAL Diagnostics's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means BCAL Diagnostics's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

BCAL Diagnostics's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means BCAL Diagnostics's Accounts Payable & Accrued Expense stayed the same from Jun. 2022 to Jun. 2023 .

BCAL Diagnostics Change In Payables And Accrued Expense Historical Data

The historical data trend for BCAL Diagnostics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Change In Payables And Accrued Expense Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Change In Payables And Accrued Expense

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial			-	-	-	-	-

BCAL Diagnostics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

BCAL Diagnostics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.